Cidara Therapeutics Inc. (Nasdaq: CDTX) reported upbeat results from a Phase 2 STRIVE clinical trial of its lead anti fungal candidate rezafungin acetate but the stock price tumbled $1.90 to close at $6.00.
Cidara Therapeutics reports positive study results
March 19, 2018 at 17:32 PM EDT
